Gunars Gaikis has over 30 years of experience in IP law and the procurement, litigation and enforcement of pharmaceutical and biotechnology patent rights and strategic advising. He has appeared as lead counsel in many precedent setting IP cases before the Ontario, Federal and Supreme courts, including the June 30, 2017 Supreme Court of Canada decision in AstraZeneca v Apotex, which struck down the “promise of the patent” utility doctrine.
Gunars is recognized as one of the world’s foremost experts in Who’s Who Legal: Thought Leaders 2019 and has obtained one of the highest number of nominations from peers and corporate counsel. In 2018 he was named ‘Canadian Patent Litigation Attorney of the Year’ at the LMG Life Sciences Awards, and ‘Outstanding IP Practitioner of the Year in Canada’ by Managing Intellectual Property. He is recognized annually as a World IP Review Leader and as among the top 30 patent attorneys in the world by Expert Guides: Best of the Best. Chambers Global – The World’s Leading Lawyers has listed Gunars under Intellectual Property Litigation since 2006 and Chambers Canada has named him as a leading lawyer for Intellectual Property Litigation since 2016. Gunars is also listed in the Lexpert® Guide to the Leading US/Canadian Cross-Border Litigation Lawyers in Canada, Expert Guides: Patents, Who’s Who Legal: Life Sciences and Patents, MIP’s IP Stars Handbook: Patents and IAM Patent 1000.
Recently Gunars was nominated for the 2018 ‘IP Litigation Lawyer of the Year in Canada’ and named one of the ‘Top 50 Trial Lawyers’ by Benchmark Canada.
He is a Canada Licensed pharmacist and registered Patent and Trademark Agent.
J.D. (Osgoode Hall), Called to the Ontario Bar in 1983.
Last updated: Feb 2019